Sun Pharma eyes Organon buy

A Mumbai drugmaker that usually buys in smaller bites is now lining up money for a meal big enough to redraw Indian pharma’s map. Sun Pharmaceutical Industries is preparing a binding all-cash offer of about $12 billion for Organon, and banks are discussing how to finance it. (economictimes.indiatimes.com) (outlookbusiness.com) If it happens, this would be the largest overseas acquisition ever attempted by an Indian pharmaceutical company. Outlook Business reported that Sun has finished more than three months of due diligence and is assembling debt, cash, and bridge financing with JPMorgan, Mitsubishi UFJ Financial Group, Standard Chartered, and Citi. (outlookbusiness.com) Organon is not a startup with one miracle drug. It is a New Jersey drug company that Merck spun off on June 3, 2021, with businesses in women’s health, biosimilars, and older branded medicines that still sell at scale. (merck.com) (ft.com) That mix explains why Sun is looking. Sun already sells branded generics, generics, and innovative medicines in more than 100 countries, and Organon would add a ready-made portfolio in women’s health and biosimilars instead of forcing Sun to build those franchises country by country. (sunpharma.com) (outlookbusiness.com) Sun is big enough to think about a deal like this, but not so big that $12 billion is casual. In its January 31, 2026 results, Sun reported nine-month sales of 436.6 billion rupees, and its equity market value in early April 2026 was about 4.15 trillion rupees, so the proposed price is a very large bet even for India’s biggest drugmaker. (sunpharma.com) (stockanalysis.com) Organon brings scale, but it also brings baggage. Organon said on February 12, 2026 that full-year 2025 revenue was $6.2 billion and adjusted earnings before interest, taxes, depreciation, and amortization were $1.91 billion, while the company was still focused on “deleveraging,” which is corporate shorthand for paying down debt. (organon.com) (sec.gov) The pressure points are visible inside the business. Organon’s fourth-quarter 2025 women’s health revenue fell 15% to $398 million, while biosimilars rose 11% to $181 million, so a buyer would be purchasing a company with one engine slowing and another still trying to get bigger. (organon.com) One product shows the problem in miniature. Organon said sales of Nexplanon, its contraceptive implant, fell 20% excluding currency effects in the fourth quarter because of changes in United States wholesaler sales practices, lower demand tied to access restrictions, and higher rebates. (organon.com) That is why the financing matters as much as the headline price. An all-cash offer means Sun would need to arrive with real money on day one, and any heavy borrowing would leave it trying to digest Organon’s debt load while also protecting its own balance sheet. (economictimes.indiatimes.com) (outlookbusiness.com) There is also no guarantee Sun gets a clear run. Outlook Business reported that Morgan Stanley is exploring options for Organon and that two other international consortiums are also in the mix, which means Sun may still be in a bidding contest rather than a straight negotiation. (outlookbusiness.com) The market’s first reaction was simple: Organon jumped. MarketWatch reported the stock rose sharply in premarket trading on April 10 after the bid report, because investors heard “cash offer” and immediately started recalculating what the company might be worth in a sale instead of as a standalone turnaround. (marketwatch.com) If Sun goes through with it, the company would be moving beyond the old Indian pharma playbook of selling lots of lower-cost pills in many markets. It would be buying a United States-listed platform with $6.2 billion in annual revenue, a women’s health franchise, a biosimilars beachhead, and a debt problem large enough to make the next chapter much harder than signing the offer letter. (organon.com) (merck.com)